Activation of monocytes in vivo causes intracellular accumulation of lipoprotein-derived lipids and marked hypocholesterolemia—a possible pathogenesis of necrobiotic xanthogranuloma

Matsuura, Fumihiko; Yamashita, Shizuya; Hirano, Ken‐ichi; Ishigami, Masato; Hiraoka, Hisatoyo; Tamura, Ritsu; Nakagawa, Tsutomu; Nishida, Makoto; Sakai, Naohiko; Nakamura, Tadashi; Nozaki, Satoshi; Funahashi, Tohru; Matsumoto, Chiho; Higashiyama, Mari; Yoshikawa, Kunihiko; Matsuzawa, Yūji

doi:10.1016/s0021-9150(98)00260-3

Cited by 59 publications

(41 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, OPN is expressed in bone (especially in the metaphyseal and periosteal bone) [24], pituitary [25], mammary glands [26], kidney and lung [27], the distribution spectrum of which is quite similar to those of xanthogranulomas in ECD, where xanthogranulomatous infiltration of macrophages occurs. Furthermore, in necrobiotic xanthogranuloma, macrophages expressing OPN are reported to contribute to the intracellular accumulation of lipoprotein-derived lipids leading to non-inherited xanthomatosis [28]. Thus, we speculated that the expression of OPN could be a marker of the disease activity of ECD.…”

Section: Discussionmentioning

confidence: 96%

Erdheim-Chester Disease: Report of a Case with PCR-based Analysis of the Expression of Osteopontin and Survivin in Xanthogranulomas Following Glucocorticoid Treatment

et al. 2008

View full text Add to dashboard Cite

Abstract. Erdheim-Chester disease (ECD) is a form of non-Langerhans histiocytosis. In this report, we show a case of ECD presenting diabetes insipidus and multiple xanthogranulomas received glucocorticoid treatment over a year. During this period, xanthogranulomas improved in response to the glucocorticoid therapy. Furthermore, the expression of osteopontin in xanthogranulomatous tissues significantly decreased following the treatment. Our data show the expression of osteopontin in xanthogranulomatous tissues of ECD. Furthermore, the osteopontin mRNA decreased following glucocorticoid therapy with xanthogranuloma regression, suggesting that the expression level of osteopontin could be a marker of the disease activity of ECD.

show abstract

Section: Discussionmentioning

confidence: 96%

Erdheim-Chester Disease: Report of a Case with PCR-based Analysis of the Expression of Osteopontin and Survivin in Xanthogranulomas Following Glucocorticoid Treatment

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The pathogenesis of NXG is still obscure. It was hypothesized that lipid-laden monocytes and immunoglobulins are deposited in the skin and elicited a giant cell inflammatory reaction [3]. On the contrary, M-protein may be the primary abnormality, and skin lesions arise from secondary proliferation of macrophages bearing receptors for Fc portion of their M-protein [4].…”

Section: Discussionmentioning

confidence: 99%

Periorbital necrobiotic xanthogranuloma without paraproteinemia

Nakamura-Wakatsuki¹,

Yamamoto²

2013

Our Dermatol Online

View full text Add to dashboard Cite

Introduction: Necrobiotic xanthogranuloma (NXG) is a rare histiocytic disease which most frequently involves periorbital areas. NXG is associated with paraproteinemia with a ratio over 80%. However, a few cases of NXG without paraproteinemia (isolated NXG) have also been reported. Main observation: A 58-year-old Japanese woman complained about asymptomatic dermal nodules on the bilateral lower eyelids. The histopathological examination revealed granulomatous inflammation. Paraproteinemia was not detected either in the serum or in the urine. The size of the nodules has been constant, and she has been under careful follow-up without any systemic therapies. Conclusions: NXG is frequently associated with paraproteinemia, which may develop later. Patients with NXG need careful follow-up including repeated blood tests.

show abstract

“…They are triggered by deposition of immunoglobulins and lipid complexes in affected tissues. 2 Improvement of skin lesions has been seen with systemic corticosteroids, chlorambucil, melphalan, radiotherapy, interferon a-2a, and plasmapharesis. Intralesional injection of triamcinolone may be beneficial for accessible lesions.…”

Section: Commentmentioning

confidence: 99%